NEW YORK (360Dx) – Quidel said Wednesday that it has received CE marking for its Thyretain TBI Reporter BioAssay used in the qualitative detection in serum of autoantibodies that block thyroid-stimulating hormone receptors.

Quidel’s assay employs a patented technology to detect thyroid-blocking immunoglobulin (TBI) and enables highly complex laboratories to diagnose autoimmune thyroiditis in a few days. Until now, a method to detect it has not been available in the market, the firm said.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.